COMPANY PROFILE

RNAimmune

Explore full profile

The company's focus is on developing treatments and cures for complex diseases using mrna technology

Gaithersburg, United StatesFounded 2020Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About RNAimmune

RNAimmune is a biotechnology startup specializing in messenger RNA (mRNA) technology. The company focuses on developing treatments for cancer, antibody therapies, rare diseases, and prophylactic vaccines. RNAimmune's proprietary technology uses mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company operates in the biotechnology and pharmaceutical markets, serving clients in the healthcare sector, including hospitals, research institutions, and pharmaceutical companies. RNAimmune generates revenue through the development and licensing of its mRNA-based therapies and vaccines. The company's leadership team includes industry veterans with extensive experience in drug development and pharmaceutical research, ensuring a strong foundation for innovation and growth.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Gaithersburg, United States
Employees: 9
Open positions: None listed
Dealroom signal: 33.1/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Mar 2022	$27M	$108M	Rotating Boulder Fund · Sirnaomics	↗
SEED✓Equity / VC	Apr 2021	$10M	$40M	Terra Magnum Capital Partners · Smooth River · High Forest Investment · Shanghai Walga Biotechnology	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

RNAimmune website traffic

Latest recorded traffic for RNAimmune is 1.8K monthly website visits, up 80% over the last three months. RNAimmune's team grew 0% over the past year.

Latest monthly visits1.8K 3-month web change+80% 1-year team growth0%

Monthly website visitsAug 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
FUFuturedMeFuturedMe Inc.- A pioneer in the science of using novel protein degradation CANDDYTM Platform towards “No Patients without Medicine”-	Tokyo, Japan	Operational	—	$12M	$21M
LALajollalabsHigh-Throughput Screening Technology for Drug Discovery	San Diego, United States	Operational
1T1E TherapeuticsFocuses on developing oligonucleotide therapeutics to treat various diseases	Rehovot, Israel	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
RPRectify PharmaceuticalsBreakthrough ABC transporter platform enabling rapid discovery of small molecule therapies for liver, biliary, eye, CNS, and cardiometabolic diseases	Cambridge, United States	Operational
TRtranScripSpecialist pharmaceutical consultancy for the entire product lifecycle	Wokingham, United Kingdom	Acquired
SBSynkrino BiotherapeuticsLeverages deep industry experience and technical expertise to pinpoint early-stage ventures in under-served healthcare sectors where significant ongoing support can maximize efficiencies and produce superior returns	St. Louis, United States	Operational